The late-stage biopharmaceutical company is leveraging capital investment to advance its soft mist inhaled insulin product toward phase III trials and build a leadership team.
News & Features
The donor-derived cell-free DNA test was developed by the National Institutes of Health/National Heart Blood and Lung Institute.
Prompted by a recent publication in the Journal of the American Heart Association that suggests a possible increased risk of death at two years and beyond in patients treated with vascular balloons coated with paclitaxel or stents that release paclitaxel, FDA said it is evaluating data and working directly with manufacturers to better understand this issue.
A student has won a global competition for her efforts to develop a synthetic material that could act as both a diagnostic and a therapeutic agent for bacterial toxins.
The Dublin-based company is launching a post-market study that will evaluate the use of the SynchroMed II intrathecal drug delivery system as an alternative to oral opioids.
The test, developed by Researchers at the Institute for Global Food Security at Queen’s University Belfast, can detect proteases, enzyme markers that are responsible for the progression of many diseases.
Focus on strategies that treat patients before they go on opioids, says a medical doctor and medtech innovator speaking in an upcoming MD&M West 2019 panel discussion.
Israel-based Itamar Medical plans to use the net proceeds to accelerate its revenue growth through direct expansion of its sales and marketing initiatives.
FDA cannot accept new 2019 user fees during the government shutdown, which means the agency cannot accept new medical product applications.
The collaboration will use the Apple Watch to measure the outcomes of J&J’s heart health engagement program.
The acquisition comes hot on the heels of Boston Scientific making a significant acquisition into the mitral valve space.
The Irvine, CA-based company is slated to pay out $180 million to Boston Scientific in a move that would end both firms’ outstanding TAVR lawsuits and injunctions.
Abbott says its Amplatzer Piccolo Occluder is the first device approved for use in the tiniest babies (weighing as little as two pounds) to treat patent ductus arteriosus, a common congenital defect.